Supraophthalmic intracarotid infusion of bcnu for malignant glioma

Sun Hoo Foo; In Sup Choi; Alejandro Berenstein; Arlene Wise; Joseph Ransohoff; Maxim Koslow; Ajax George; Jokph Lin; Irwin Feigin; Gleb Budzilovich; Mark Kupersmith; Richard Hanson; Steve Lequerica; Slobodan Aleksic; Irvin Kricheff

doi:10.1212/wnl.36.11.1437

Supraophthalmic intracarotid infusion of bcnu for malignant glioma

Sun Hoo Foo, In Sup Choi, Alejandro Berenstein, Arlene Wise, Joseph Ransohoff, Maxim Koslow, Ajax George, Jokph Lin, Irwin Feigin, Gleb Budzilovich, Mark Kupersmith, Richard Hanson, Steve Lequerica, Slobodan Aleksic, Irvin Kricheff

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

We treated five patients with 11 supraophthalmic infusions of BCNU at 200 mg/m² every 2 months. All three patients with residual tumors showed marked CT response after one infusion. Two patients with bilateral tumors had no response on the contralateral side. All four evaluable cases showed evidence of BCNU neurotoxicity. CT findings superficially resembled tumor recurrence, but white matter changes, nonspecific gyral enhancement, and delayed calcification were more indicative of neurotoxicity. There were no procedure-related complications. One autopsy suggested that direct parenchymal damage might be responsible for delayed neurotoxicity. Supraophthalmic BCNU infusion, at this dosage, is too toxic for cerebral tissue.

Original language	English
Pages (from-to)	1437-1444
Number of pages	8
Journal	Neurology
Volume	36
Issue number	11
DOIs	https://doi.org/10.1212/wnl.36.11.1437
State	Published - Nov 1986
Externally published	Yes

Access to Document

10.1212/wnl.36.11.1437

Cite this

@article{4e3864f31e024a2c819d0ab0cbb3c033,

title = "Supraophthalmic intracarotid infusion of bcnu for malignant glioma",

abstract = "We treated five patients with 11 supraophthalmic infusions of BCNU at 200 mg/m2 every 2 months. All three patients with residual tumors showed marked CT response after one infusion. Two patients with bilateral tumors had no response on the contralateral side. All four evaluable cases showed evidence of BCNU neurotoxicity. CT findings superficially resembled tumor recurrence, but white matter changes, nonspecific gyral enhancement, and delayed calcification were more indicative of neurotoxicity. There were no procedure-related complications. One autopsy suggested that direct parenchymal damage might be responsible for delayed neurotoxicity. Supraophthalmic BCNU infusion, at this dosage, is too toxic for cerebral tissue.",

author = "Foo, {Sun Hoo} and Choi, {In Sup} and Alejandro Berenstein and Arlene Wise and Joseph Ransohoff and Maxim Koslow and Ajax George and Jokph Lin and Irwin Feigin and Gleb Budzilovich and Mark Kupersmith and Richard Hanson and Steve Lequerica and Slobodan Aleksic and Irvin Kricheff",

year = "1986",

month = nov,

doi = "10.1212/wnl.36.11.1437",

language = "English",

volume = "36",

pages = "1437--1444",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - Supraophthalmic intracarotid infusion of bcnu for malignant glioma

AU - Foo, Sun Hoo

AU - Choi, In Sup

AU - Berenstein, Alejandro

AU - Wise, Arlene

AU - Ransohoff, Joseph

AU - Koslow, Maxim

AU - George, Ajax

AU - Lin, Jokph

AU - Feigin, Irwin

AU - Budzilovich, Gleb

AU - Kupersmith, Mark

AU - Hanson, Richard

AU - Lequerica, Steve

AU - Aleksic, Slobodan

AU - Kricheff, Irvin

PY - 1986/11

Y1 - 1986/11

N2 - We treated five patients with 11 supraophthalmic infusions of BCNU at 200 mg/m2 every 2 months. All three patients with residual tumors showed marked CT response after one infusion. Two patients with bilateral tumors had no response on the contralateral side. All four evaluable cases showed evidence of BCNU neurotoxicity. CT findings superficially resembled tumor recurrence, but white matter changes, nonspecific gyral enhancement, and delayed calcification were more indicative of neurotoxicity. There were no procedure-related complications. One autopsy suggested that direct parenchymal damage might be responsible for delayed neurotoxicity. Supraophthalmic BCNU infusion, at this dosage, is too toxic for cerebral tissue.

AB - We treated five patients with 11 supraophthalmic infusions of BCNU at 200 mg/m2 every 2 months. All three patients with residual tumors showed marked CT response after one infusion. Two patients with bilateral tumors had no response on the contralateral side. All four evaluable cases showed evidence of BCNU neurotoxicity. CT findings superficially resembled tumor recurrence, but white matter changes, nonspecific gyral enhancement, and delayed calcification were more indicative of neurotoxicity. There were no procedure-related complications. One autopsy suggested that direct parenchymal damage might be responsible for delayed neurotoxicity. Supraophthalmic BCNU infusion, at this dosage, is too toxic for cerebral tissue.

UR - http://www.scopus.com/inward/record.url?scp=0022998968&partnerID=8YFLogxK

U2 - 10.1212/wnl.36.11.1437

DO - 10.1212/wnl.36.11.1437

M3 - Article

C2 - 3762962

AN - SCOPUS:0022998968

SN - 0028-3878

VL - 36

SP - 1437

EP - 1444

JO - Neurology

JF - Neurology

IS - 11

ER -

Supraophthalmic intracarotid infusion of bcnu for malignant glioma

Abstract

Access to Document

Fingerprint

Cite this